Skip to content

Clinical trials

Observational Muscular Dystrophies trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Muscular Dystrophies Phase: Observational Country / region: United States Clear all

44 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20051
20061
20072
20092
20102
20112
20125
20132
20141
20152
20161
20181
20192
20201
20211
20224
20233
20241
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed17
Recruiting14
Unknown status4
Active, not recruiting3
Terminated3
Enrolling by invitation2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Neurological Disorders and Stroke (NINDS)5
Cooperative International Neuromuscular Research Group4
Virginia Commonwealth University4
Wake Forest University Health Sciences4
Beth Israel Deaconess Medical Center2
The Duchenne Registry2
University of Kansas Medical Center2
Baylor College of Medicine1
BioMarin Pharmaceutical1
Casa Colina Hospital and Centers for Healthcare1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Muscular Dystrophies44
Muscular Dystrophy, Duchenne13
Muscular Dystrophies, Limb-Girdle6
Myotonic Dystrophy6
Amyotrophic Lateral Sclerosis5
Muscular Diseases5
Neuromuscular Diseases5
Arrhythmias, Cardiac3
Motor Neuron Disease3
Muscle Weakness3

Trials

Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.